PEG Glyconanoparticle Production Service
Overview
Polyethylene glycol (PEG) glyconanoparticles are a rapidly emerging research focus in the fields of nanoscience and biochemistry. In the biomedical field, conventional drug delivery and therapeutic methods often face many challenges, such as low bioavailability, poor targeting and immunogenic reactions, etc. The emergence of PEG glyconanoparticles provides a new way of thinking to solve these problems. The PEG layer on their surface endows the particles with good water solubility and biocompatibility, which reduces the interaction with the immune system and prolongs the circulation time of the particles in the body. Meanwhile, the introduction of sugar groups brings specific recognition and binding ability to the particles, enabling them to precisely target specific cells or tissues. This property shows great potential in cancer therapy, disease diagnosis, and bioimaging. In addition, advances in materials science have provided technical support for the preparation and performance optimization of PEG glyconanoparticles. The development of various synthetic methods has enabled the precise tuning of particle size, shape, and surface properties to meet the needs of different applications.
Our PEG Glyconanoparticle Production: Where Quality Meets Creativity!
CD BioGlyco has a state-of-the-art GlycoNano™ Platform. This platform integrates cutting-edge scientific concepts, superb technology, and efficient production processes. With its powerful functions and excellent performance, we provide professional and high-quality Glyconanoparticle Development Services to our clients. The glyconanoparticles included in our services include but are not limited to Gold Glyconanoparticles, Silver Glyconanoparticles, Magnetic Glyconanoparticles, Quantum Dot (QD) Glyconanoparticles, and PEG glyconanoparticles. The PEG glyconanoparticle production service includes but is not limited to the following.
PEG-coated Upconversion Nanoparticle (UCNP) Production Service
Our service is characterized by cutting-edge technology and professional expertise. We ensure that the PEG-coated UCNPs produced meet the highest quality standards and are tailored to your specific needs.
PEG-modified UCNP Production Service
Our production process is based on the latest advancements in technology and strict quality control measures to ensure that the final products meet and exceed your expectations.
Workflow
Selection of PEG
Firstly, we select the appropriate molecular weight of PEG, taking into account its influence on the stability and half-life of nanoparticles. Generally, larger PEG chains (e.g., with molecular weights ranging from 2000 Da to 20,000 Da) usually offer better stability and longer circulation times. The specific selection will depend on the desired biocompatibility and drug release characteristics. For instance, higher molecular weights might increase the blood circulation time of nanoparticles, but could also have an impact on their biodegradability.
PEG Linkage and PEGylation
PEG can be attached to the surface of nanoparticles by covalent or non-covalent methods. For solid nanoparticles (e.g., gold nanoparticles), a common covalent attachment method is to utilize sulfhydryl groups (thiol) to bind to the gold surface. For other types of nanoparticles (e.g., silicon nanoparticles), we usually use organosilanes for biocoupling. We synthesize the desired nanoparticles and react the selected PEG with them to guarantee that the PEG chains can be effectively attached to the nanoparticle surface. This can be accomplished either by mixing the PEG with the nanoparticles or by chemically binding the PEG chains to the nanoparticle surface. Subsequently, unbound PEG and other impurities are removed through centrifugation, washing, filtration, or dialysis to obtain a pure PEG Glyconanoparticle.
Characterization
Our characterization of the synthesized PEG glyconanoparticles is typically carried out through a diverse range of methods. For instance, the hydrodynamic diameter of the particles is gauged by dynamic light scattering (DLS) to determine the size distribution. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) are employed to envision the size, shape, internal structure, and surface morphology of the particles. X-ray photoelectron spectroscopy (XPS) is utilized to analyze the chemical composition and elemental valence of the surface to understand the surface properties. Fourier transform infrared spectroscopy (FTIR) is adopted to detect functional groups to confirm PEG coverage and binding. Thermogravimetric analysis (TGA) is also employed to ascertain the PEG content or the chemical structure of the particles is analyzed with the help of nuclear magnetic resonance (NMR).

Applications
- PEG glyconanoparticles can be used for drug delivery to achieve targeted delivery to specific cells or tissues, improving the therapeutic efficacy of drugs and reducing side effects.
- Due to their unique optical or magnetic properties, they can be used for fluorescence imaging, photoacoustic imaging, etc. to help visualize physiological and pathological processes in living organisms.
- It can be used to detect specific biomolecules in organisms, such as proteins and nucleic acids, for early diagnosis of diseases.
Advantages
- Our optimized production technology reduces residues of impurities and hazardous substances, lowering the potential toxicity to living organisms.
- We precisely control the size, shape, and surface properties of the particles to meet the specific needs of different application scenarios.
- Our manufacturing process ensures that the particles have good physical and chemical stability, prolonging their preservation and use outside the body.
Publication Data
Technologies: FTIR, TGA
Journal: Frontiers in Chemistry
Published: 2023
IF: 3.97
Results: This article centers on the characterization of UCNPs and their utilization in biomedicine, particularly in cell imaging and drug delivery. The article elaborates on the basics of UCNPs, their synthesis approaches, and their benefits in bioimaging, like the capacity to be stimulated by near-infrared light and transformed into visible light for deep tissue imaging. The polymer-coated hexagonal UCNPs exhibited excellent characteristics in terms of chemical stability and cytotoxicity, especially UCNP@Ale-PDMA and UCNP@Ale-PEG nanoparticles with high potential for intracellular uptake and biocompatibility. It was demonstrated that these nanoparticles retain high cell viability in cell culture even at high concentrations and that there are notable distinctions in the effects of different kinds of polymer coatings on cells. This study is the first comprehensive exploration of the solubility of UCNPs larger than 100 nm, offering insights into their potential influence in biomedical applications.
Fig.1 Attenuated total reflectance (ATR) FTIR spectra and upconversion photoluminescence emission spectra of hexagonal UCNPs with and without polymer coating. (Patsula, et al., 2023)
Frequently Asked Questions
- How are manufactured PEG glyconanoparticles stored and transported?
Generally, they need to be stored under specific temperature, humidity, and aseptic conditions, and packaged and transported appropriately to ensure their stability and activity. -
How is quality control performed during the production process?
During the synthesis process, the reaction conditions such as temperature, pressure, reaction time, and pH are monitored in real-time, and the intermediate products generated at each stage are analyzed to determine the correct chemical composition and structure with the help of high-performance liquid chromatography and mass spectrometry.
CD BioGlyco is committed to offering you top-notch PEG glyconanoparticle production services. Thanks to our cutting-edge production facilities and seasoned team of experts, we tailor high-quality PEG glyconanoparticles in line with your particular requirements and specifications. Please feel free to contact us if you are interested in our service!
Reference
- Patsula, V.; et al. Polymer-coated hexagonal upconverting nanoparticles: Chemical stability and cytotoxicity. Frontiers in Chemistry. 2023, 11: 1207984.
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





